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Postoperative intra-abdominal adhesions represent a serious clinical problem. In this review, we have
focused on recent progress in the cellular and humoral mechanisms underpinning adhesion formation,
and have reviewed strategies that interfere with these pathways as a means to prevent their occurrence.
Current and previous English-language literature on the pathogenesis of adhesion formation was
identiﬁed. As the burden of surgical disease in the world population increases, and the frequency of
reoperation increases, prevention of adhesion formation has become a pressing goal in surgical research.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Enduring as a surgical footprint, post-operative peritoneal
adhesions present a challenging problem for surgeons and their
patients. They develop following abdominal and pelvic surgery as
a response to tissue trauma to peritoneal surfaces. They are nearly
always encountered on reoperation: in a prospective analysis of 210
patients undergoing a laparotomy with one or more previous
abdominal operations, 93% had adhesions, compared with 10.4% in
ﬁrst-time laparotomy patients.1
In this review, we review the work that has been done to eluci-
date the pathophysiology of adhesion development with a focus on
recent studies of the cellular and humoral mechanisms. In this
context of new discoveries, we will discuss future techniques and
research direction.
1.1. The spectrum and cost of morbidity
As the incidence of abdominal surgery increases worldwide, so
does the incidence of adhesions; as longevity increases, so too does
the incidence of relaparotomy. Though there are few cohort studies,
the Surgical and Clinical Adhesions Research (SCAR) group was
formed in the UK to address the issue. In one retrospective study of
29,970 patients in the UK, in the ten years following their abdom-
inal or pelvic surgery, 34.6% were readmitted a mean of 2.1 times
for a disorder directly or possibly related to adhesions.2
The most serious complication of adhesions is intestinal
obstruction, accounting for more than 40% of all cases of: þ1 780 407 8259.
).
ciates Ltd. Published by Elsevier Ltobstruction and 60e70% of small bowel obstructions.3 Adhesions
can prevent a safe surgical entry into the abdomen, and also
increase the risk of hemorrhage and intestinal perforation. They
can preclude adequate surgical exposure, requiring dissection
that prolongs operative time,4 or in the case of laparoscopy,
hampering peritoneal insufﬂation. They are also a signiﬁcant
cause of female infertility and dyspareunia5 in addition to
urologic dysfunction.6 Pelvic pain has also been linked to adhe-
sions although this has been debated, and their lysis is usually
ineffective at relieving it.7 The problem is a very costly one:
reviewing one year in the U.S. alone, Ray et al. estimated adhe-
siolysis was responsible for 303,836 hospitalizations, amounting
to 846,415 days of inpatient care and US$1.3 billion in hospitali-
zation and surgeon costs.5
2. Etiology and pathogenesis
2.1. The peritoneum
The biology of peritoneal repair is now known to involve
a concert of chemical mediators, cytokines, cell types, degradation
products, and proteases to accomplish healing. Histologically, the
peritoneum consists of two layers: a mesothelium, one cell layer
thick, and a connective tissue layer.8 The mesothelial layer is fragile
and regenerates from injury by a simultaneous and rapid differ-
entiation over the surface, rather than from centripetal migration
from epithelial cells as is seenwith healing skin.9 The implication is
that large defects heal as rapidly as small ones. Interestingly, the
mesothelial layer is coated with a surfactant-like agent, surface-
active phospholipid (SAPL) which is theorized to serve as a “non-
stick coating”.10d. All rights reserved.
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proteins. There are also many chemical mediators present, such as
interleukins, interferon-g, TNF-a, TGF-b, and VEGF.11 Additionally
there are circulating, free macrophages and other immune cells
present in the peritoneal ﬂuid.12
Healing following surgical injury to peritoneum follows one of
two algorithms, as proposed by Duron et al.11 The ﬁrst consists of
the proliferation and regeneration of themesothelial cell layer from
an origin that has yet to be clearly identiﬁed; likely candidates
include totipotent underlying mesenchymal cells, or migration of
cells from another site (periphery of injury, nearby sites, or via
transformation of cells in peritoneal ﬂuid).11 The second is centered
on the alteration of ﬁbrinolysis, producing a “peritoneal scar,” and is
of interest in the context of adhesion formation.
Fig. 1 synthesizes putative contributory factors for adhesion
formation, and thereby potential targets for prophylaxis.2.2. The role of ﬁbrin
Many believe a tipping point in adhesion formation is the local
balance between ﬁbrin production and ﬁbrinolysis. The inciting
event of a surgical trauma or inﬂammation of the peritoneum
results in a denuded surface, submesothelial damage and injury to
blood vessels thereby invoking an inﬂammatory response.13 There
is simultaneous activation of the coagulation cascade and ﬁbrin
deposition at the site,14 which is additive with any bleeding.
Mediators such as histamine and PGE2 cause increased perme-
ability of the blood vessels in the traumatized area, and a seros-
anguinous exudate rich in inﬂammatory cells pours forth.13,15
The exudate also contains substrates such as ﬁbronectin, hya-
luronic acid, various glycosaminoglycans (GAGs), and proteogly-
cans (PGs).14 The inactive ﬁbrinogen turns to a tacky ﬁbrin matrix
gel, which may develop between two unrelated structures. UnderFig. 1. Summary of post-surgical adhesion formation. Trauma to peritoneal and other intra
cell types. These in turn serve to activate the coagulation cascade and a ﬁbrin mesh formsnormal conditions, the majority of ﬁbrinous connections are lysed
within a few days by locally released proteases of the ﬁbrinolytic
system.15 It is theorized that if they persist, ﬁbroblasts may prolif-
erate within the substrate matrix, and establish more permanent
connections.
The physiologic ﬁbrinolytic sequence is normally initiated by
plasmin. Plasmin is a fully active serine protease which is made
from plasminogen by the action of plasminogen activators (PAs).11
One PA in particular, tissue plasminogen activator (tPA), is
responsible for producing 95% of the plasmin generated in the
response to peritoneal injury.16 After surgery, tPA knockout mice
are more susceptible to adhesions.17
In a pathological state, plasminogen activator inhibitors (PAIs)
interfere with the action of PAs and the production of plasmin,
ultimately leading to an altered ability to degrade ﬁbrin split
products (ﬁbrinolysis). It has been discovered that in peritoneal
inﬂammation and injury, there are two types of PAI produced: PAI-
1 (the main ﬁbrinolytic inhibitor) and PAI-2.18,19 PAI-1 speciﬁcally
prevents the formation of plasmin by binding to and inhibiting the
activities of tPA and uPA (urokinase-like plasminogen activator).
These two serine proteases are the main activators of ﬁbrinolysis,
and thus inhibition of PAI-1 prevents the degradation of ﬁbrin.
Surgery dramatically diminishes ﬁbrinolytic activity, by increasing
levels of PAIs and by reducing tissue oxygenation.20 Eventually, in
the absence of an effective ﬁbrinolytic response, there exists a ﬁbrin
gel matrix which may serve as the scaffolding for development of
a mature adhesion.2.3. Cellular players
Following trauma, initial inﬂammatory cells are predominantly
neutrophils, with a shift to mostly macrophages at 24 h. Interest-
ingly, macrophages at the peritoneal injury site after surgery have-abdominal tissue results in an exudate rich in proinﬂammatory cytokines and various
, eventually resorbing or maturing into an adhesive connection between the surfaces.
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surgical macrophages secrete substances such as cyclooxygenase
and lipoxygenase metabolites, plasminogen activator (PA), plas-
minogen activator inhibitor (PAI), collagenase, elastase, interleu-
kins 1 and 6, tumor necrosis factor (TNF), leukotriene B4, and
prostaglandin E2.13,21 They also have the ability to recruit new
mesothelial cells to the site of the injury.22
Peritoneal macrophages in particular have been implicated as
key players in the immune response triggering adhesion formation.
They have a unique autocrine activation system whereby a che-
mokine (CCL1) and its receptor (CCR8) are released in response to
tissue damage. Migration of peritoneal macrophages (and the
development of adhesions) has been interrupted and adhesion
incidence reduced by abrogating the CCL1/CCR8 interaction.23
There is some evidence to suggest that ﬁbroblasts play a major
role in adhesion maturation. Fibroblast content increases in the
second week post-trauma, followed by the inclusion of vessel
structures and connective tissue elements.24,25 At three weeks, the
development of the adhesion becomes quite prominent.26 Rout
et al. isolated ﬁbroblasts from normal peritoneum and adhesions,
and found that they differed markedly in their phenotype.27 There
were marked effects of hypoxia and TGF-b on the expression of
some of these products in the ﬁbroblasts, suggesting some, but not
exclusive, regulatory inﬂuence of these on the pathway.27
Higher levels of degranulated mast cells have also been found in
the presence of adhesions in rats,28 and the early event of release of
vascular endothelial growth factor (VEGF) by mast cells has been
suggested to be important in adhesion development.29 Further
analysis of the cellular elements of adhesions by Binnebosel et al.
has shown inﬁltrates of macrophages and T-cells, in consistent
quantities regardless of the maturity of the adhesion.30 This char-
acterization of a state of chronic inﬂammation suggests T-cells may
play a role in signaling pathways that maintain adhesions, and
prompts consideration of adhesions as a dynamic process in
remodeling tissue.30 Certainly it is clear that adhesions can re-form
after adhesiolysis.31e34
The inﬁltration of T-cells and the perpetuation of chronic
inﬂammation in the peritoneum proceed under the inﬂuence of
many signals, including the promoting effects of IL-6 and other
cytokines.35 T-cell depletion and adoptive transfer experiments
have conﬁrmed that adhesion formation requires the presence of
CD4þ alpha beta T cells, and the production of proinﬂammatory
cytokines are dependent on T cells (IL-17 and others).36 Since many
ﬁbrotic tissue disorders share a common etiology of Tcell-mediated
abnormalities in host defense, adhesions represent an example of
this.
2.4. Humoral mediators
Immune responses, including cell trafﬁcking, are accomplished
at the cellular level by the orchestrated release of cytokines and
chemokines. Whether adhesion formation represents an abnormal
or disordered version of peritoneal healing may be considered by
examining the roles of various signaling molecules that appear
along the course of events.
2.4.1. TGF-beta
Transforming growth factor beta (TGF-b) is the most studied
cytokine in the pathophysiology of adhesion development, and has
been suggested as the principal proﬁbrotic mediator of the
process.37 In an animal model, it has been shown that intraperi-
toneal application of TGF-b to surgical adhesions resulted in
worsening of the adhesions compared with controls not given TGF-
b38 and animals given TGF-b-neutralizing antibody have shown
reduced adhesion formation39 In humans, the relationship is lessclear. In vitro, TGF-b reduces peritoneal ﬁbrinolytic capacity, an
important step in disbanding of early adhesions.40 Interestingly, it
has been observed in human peritoneal tissue that TGF-
b expression covaried with PAI-1, the main ﬁbrinolytic inhibitor.
Patients with more extensive adhesions had higher peritoneal
concentrations of TGF-b.41
2.4.2. VEGF
Vascular endothelial growth factor (VEGF) is known as a potent
angiogenic factor and may have a role in adhesion develop-
ment.42,43 It is also directly involved in early inﬂammatory
processes and wound healing by effects on ﬁbroblast function.44
In an animal model, intraperitoneal treatment with an antibody
to VEGF has resulted in a lower incidence of advanced
adhesions.45
2.4.3. Interleukins
Othermediators, such as interleukins, are receiving attention for
their role in adhesion development. Comparing serum and peri-
toneal ﬂuid levels of interleukin-1 (IL-1), post-operative patients
have a signiﬁcantly higher level in the peritoneum, suggesting
a possible local action of this interleukin.46 Rats treated pre-
operatively with anti-IL-1 had fewer adhesions postoperatively
than controls.47 Based on these and other observations, a likely
mode of action of IL-1 is to promote adhesion formation by
increasing ﬁbrin deposits, reducing ﬁbrinolysis, and stimulating
mesothelialization of the structure.12
Interleukin-6, interleukin-8 and interleukin-10 are all theorized
to participate in modulation of the cellular response to peritoneal
injury, however the roles are still not clear.12 Mesothelial cells are
the principal IL-6 secreting cells in the peritoneal cavity, and on
challenge by inﬂammation they produce large amounts of this
cytokine.48 Interleukin-6 is known for both pro- and anti-
inﬂammatory effects. When complexed with its receptor (IL-6/
sIL-6R) found on invading neutrophils, it inﬂuences a shift from
leukocyte recruitment in the acute phase of inﬂammation to an
inﬂux of sustained mononuclear leukocytes.49 A recent murine
study found that adhesions were prevented when cold saline was
infused intraperitoneally, and this correlated with lower serum IL-6
and elevated IL-10.50 Intraperitoneal injection of exogenous IL-10
has been shown to reduce post-operative adhesion formation in
a mouse model.51
2.4.4. Tumor necrosis factor-alpha
Tumor necrosis factor-alpha (TNF-a) is able to promote
production of interleukins by mesothelial cells,52 and high levels of
TNF-a in peritoneal ﬂuid and serum postoperatively have corre-
lated with adhesion severity in rats.53 However, administration of
neutralizing anti-TNF-a antibodies failed to reduce adhesion
formation, and requires further study.47
2.4.5. MMPS and TIMPS
Matrixmetalloproteinase enzymes (MMPs) and tissue inhibitors
of matrix metalloproteinases (TIMPs) vary between individuals,
and lower levels of TIMP-2 in peritoneal ﬂuid and serum is
protective.54
3. Prevention
Enormous effort both in the laboratory and the operating
theater has been applied to reduce adhesion formation. The most
common and modern approaches have been the use of a barrier
between or over damaged surfaces, administration of pharmaco-
logical agents, or a combination of these. Recent reviews include
three Cochrane reviews which compare existing evidence.55e57 Our
Table 1
Selected clinical and pre-clinical trials of barrier and pharmacological methods of
adhesion prophylaxis.
Reference Model
Barrier methods
Aloe vera gel Aysan et al., 2009 Rat
Soybean oil Aysan et al., 2009 Rat
Octyl methoxycinnamate Aysan et al., 2009 Rat
Icodextrin diZerega et al., 2002,
Menzies et al., 2006
Clinical trial,
Clinical trial
Phosphatidylcholine Ar’Rajab et al., 1991,
Roszga et al., 1990,
Snoj et al., 1992, 1993,
Treutner et al., 1995
Rat, Rat, Rat,
Rabbit
SprayGel Ferland et al., 2001 Pig
Poloxamer 407 Steinleitner et al., 1991 Rabbit
Interceed DeLaco et al., 1998,
Haney and Doty, 1992
Rabbit, Mouse
Gore-Tex Surgical Membrane Haney and Doty, 1992 Mouse
Oxidized-regenerated cellulose Haney and Doty, 1992 Mouse
Hyaluronic
acid/hyaluronan/hyaluronate,
and Sepraﬁlm
Numerous. Models have
included mouse,
rat, rabbit, as well
as clinical trials
Pharmacological methods
Aspirin Golan et al., 1995 Rat
Dexamethasone Buckenmaier et al., 1999,
Gazzaniga et al., 1975,
Hockel et al., 1987,
Kucukozkan et al., 2004
Rat, Rat, Rat,
Rabbit
Methylprednisolone Gazzaniga et al., 1975 Rat
Estrogen Bozkurt et al., 2009 Rat
Progesterone Maurer and
Bonaventura, 2003
Guinea pig
Budesonide Yeo et al., 2003 Rabbit
Heparin Bahadir et al., 2007,
Fukasawa et al., 1991
Mouse, Rabbit
Tissue plasminogen activator Buckenmaier et al.,
1999 and others
Rat
Streptokinase Buckenmaier et al., 1999 Rat
Urokinase Buckenmaier et al., 1999 Rat
Ancrod Chowdhury and
Hubbell, 1996
Rat
Mitomycin C Cubukcu et al., 2001 and
2002, Liu et al., 2005
Rat, Rat
Paclitaxel Jackson et al., 2002 Rat
Tranilast Petrilli et al., 2008 Rabbit
Methylene blue dye Heydrick et al., 2007 Rat
Taurolidine Bahadir et al., 2007,
Tarhan et al., 2008,
Treutner et al., 1995
Mouse, Rat,
Rabbit
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modiﬁcation of cellular peritoneal healing.
3.1. Barriers
Preventing contact of two traumatized surfaces with a mechan-
ical barrier has been a recurring theme in efforts to reduce adhe-
sions. Many hold the view that critical events in adhesion formation
occur by day 7,58e61 so perhaps a barrier need only be present
during an early critical window.
The mesothelial cell layer of the peritoneum is coated with
a natural anti-stick coating: a thin ﬁlm of surface-active phospho-
lipid.10 Experimental application of exogenous phospholipids has
been promising; phosphatidylcholine, sphingolipid, and gal-
actolipid62 have decreased the areas of post-operative adhesion in
animal studies. Phosphatidylcholine has been shown in several
studies to have a beneﬁcial effect in the rat,63e66 but with the side
effect of impaired healing of intestinal anastomoses at higher
concentrations. Applying Poloxamer 407, a polymer of hydrophilic
non-ionic surfactant, after adhesiotomy in an animal model has
reduced the incidence of re-formation of adhesions. It has yet to be
studied in humans.67
Hyaluronic acid, also called hyaluronan or hyaluronate, has long
been a subject of antiadhesion research. It is a naturally occurring
glycosaminoglycan and forms a highly viscous solution to coat
serosal surfaces. In a single intraperitoneal dose at time of opera-
tion, Treutner et al. found the mean area of adhesions reduced by
84% compared to control in their animal model.62 Other animal
studies have shown a reduction of adhesion formation when the
hyaluronic acid was applied before the trauma, but not a reduction
in reformation after the division of existing adhesions.68,69
The introduction of barriers into general clinical practice has
been restricted by several factors. Though a few are commercially
available, drawbacks include difﬁculties in preparation and appli-
cation, the need for absolute hemostasis, insufﬁcient pliability,
intricate product ﬁxation techniques, and incompatibility with
laparoscopic surgical procedures.70 Without clear understanding of
how these agents might interfere with normal intra-abdominal
wound healing, their use deserves caution.
3.2. Pharmacological methods
With the discovery of new components of adhesion formation,
manipulating the cellular milieu to disfavor adhesiogenesis and
promote normal peritoneal resolution becomes an appealing
prospect.
Many different agents have been used in the effort to arrest the
adhesion pathway or to tip the balance in the favor of ﬁbrinolysis
and adhesion resorption. Drugs may be administered systemically,
or ideally, locally with minimal systemic effect. The peritoneal
cavity is an efﬁcient site for uptake of large molecules; even
particles the size of cells may pass through the lymphatic lacunae
located in the submesothelial layer.
The inﬂammatory component of the pathogenesis of adhesion
formation has been targeted, and a variety of steroidal and anti-
inﬂammatory drugs have been studied, including aspirin, dexa-
methasone, methylprednisolone, estrogen, progesterone and
budesonide.71e78 However, the effectiveness of these agents has
not been consistent in animal models and clinical trials.79
Heparin has been suggested in an attempt to moderate activa-
tion of the clotting cascade and reduce ﬁbrin deposition contrib-
uting to the process of adhesion formation. There is some evidence
from animal models to suggest local intraperitoneal administration
of low-dose heparin may result in fewer adhesions.80 Removal of
already-formed ﬁbrin using trypsin, pepsin, papain, as well asmechanical removal by lavage and by hand has produced incon-
sistent and anecdotal results.
Other targets of the ﬁbrin-ﬁbrinolysis pathway include use of
ﬁbrinolytic drugs and plasminogen activating factor.58,73,81e83
These have been effective in a dose-dependent manner84 but are
noted to impair wound healing. Ancrod, an experimental deﬁb-
rinogenating agent made from Malayan pit viper venom, has been
used experimentally in combination with a hydrogel to reduce
adhesions.85 Since all ﬁbrinolytic drugs can incite bleeding,
acceptance for routine use in the prevention of post-operative
adhesions is unlikely.
There may be a role for several medications approved for other
indications, such as mitomycin C, paclitaxel, sirolimus and taur-
olidine. Mitomycin C is an antitumor antibiotic that can inhibit
ﬁbroblast proliferation for several weeks in vitro. It has been
combined with a crosslinked hyaluronan hydrogel for the purposes
of adhesion reduction in an animal model.70 It has also been used
locally in strabismus surgery to limit post-operative adhesion,
a property which is attributed to its antiﬁbrinolytic activity,86 and
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Antiproliferative agents such as paclitaxel and sirolimus may also
have promising applications in adhesion reduction devices.
Paclitaxel-loaded crosslinked hyaluronic acid ﬁlms reduced adhe-
sion incidence in a rat model,88 while sirolimus has been used
experimentally in an animal aortic PTFE vascular graft model to
reduce retroperitoneal adhesions.89 Taurolidine is a drug with
antimicrobial and anti-lipopolysaccharide properties, and has
immune modulatory action via priming and activation of macro-
phages. It has also been tested in experimental animal models to
reduce adhesions, with inconsistent results.62,90,91
A summary of selected pre-clinical and clinical trials of devices
and drugs is provided in Table 1. Given the location of drug delivery
and barrier placement, there are obvious implications for biocom-
patibility and toxicity of any material used for adhesion preven-
tion.12 The future of adhesion prevention strategy likely has the
most promise in a device which combines targeted pharmacology
with a barrier method.
4. Conclusion
Postoperative adhesions represent a problem of considerable
magnitude. Morbidity resulting from adhesive tissue following
surgery may be substantial, and is a burden the patient carries for
the rest of their lives. From our increased understanding of the
multifactorial nature of adhesion pathogenesis, and our growing
knowledge of the effects of cellular and molecular mediators of the
process, there is hope that a preventative strategy will emerge.
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